Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Transplant Rejection Clear all
Not listed Phase 4 Interventional

Single Dose rATG for Renal Allograft Rejection

NCT02102854
View directory record Official record
Conditions
Acute (Cellular) Renal Allograft Rejection
Interventions
rATG
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 23, 2026, 1:01 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 23, 2026, 1:01 PM EDT
Completed No phase listed Observational

Study of Tolerant Kidney Transplant Recipients

NCT01338779
View directory record Official record
Conditions
Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant, Transplant Tolerance
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269
View directory record Official record
Conditions
Kidney Transplantation
Interventions
basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 23, 2026, 1:01 PM EDT
Terminated Early Phase 1 Interventional Results available

Research Study of ATG and Rituximab in Renal Transplantation

NCT01318915
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
ATG, Rituximab, Tacrolimus, Sirolimus, MMF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 23, 2026, 1:01 PM EDT
Terminated Phase 3 Interventional

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

NCT00000936
View directory record Official record
Conditions
Kidney Transplantation
Interventions
hOKT3, Oral Cyclosporine, IV Cyclosporine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 1:01 PM EDT
Completed No phase listed Observational

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

NCT00805571
View directory record Official record
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 23, 2026, 1:01 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 1:01 PM EDT
Not yet recruiting No phase listed Observational

GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial

NCT07551531
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
Insight Molecular Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 1:01 PM EDT
Active, not recruiting Phase 2 Interventional

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
View directory record Official record
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

NCT01134510
View directory record Official record
Conditions
Kidney Transplantation
Interventions
C1 Esterase Inhibitor, Placebos
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"

NCT00365846
View directory record Official record
Conditions
Renal Transplant
Interventions
Campath-1H
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 23, 2026, 1:01 PM EDT
Completed No phase listed Observational

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

NCT03317925
View directory record Official record
Conditions
Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions
Renal Transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Year to 20 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 1:01 PM EDT
Withdrawn Phase 2 Interventional

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

NCT01035593
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
plasmapheresis and IVIG, recombinant C1 inhibitor
Procedure · Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 23, 2026, 1:01 PM EDT
Completed No phase listed Observational Results available

The Differential Effects of 3 Different Immunosuppressive

NCT00729248
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 3 Interventional

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

NCT00097968
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 23, 2026, 1:01 PM EDT
Terminated No phase listed Observational

TruGraf® Testing in High-Risk Kidney Transplant Recipients

NCT04266613
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 23, 2026, 1:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 1:01 PM EDT
Completed No phase listed Observational

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Retrospective Cohort Enrollment, Prospective Cohort Enrollment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

NCT02426684
View directory record Official record
Conditions
Renal Disease
Interventions
IdeS® (Imlifidase)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 23, 2026, 1:01 PM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 1:01 PM EDT